Navigation Links
arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients
Date:1/13/2014

>

About the ARGX-110 Study

The Phase Ib study (ClinicalTrials.gov Identifier: NCT01813539) consists of a dose escalation phase followed by adaptive safety and efficacy expansion cohorts conducted in patients with advanced, refractory cancer. The patient enrichment strategy relies on individual tumor screening for CD70 utilizing a reproducible immunohistochemistry method. In addition to traditional clinical and PK/PD endpoints, biomarkers documenting the three modes of action of ARGX-110 are being evaluated. Patient enrolment is planned at approximately 90 CD70-positive patients with either haematological or solid tumors. The study is managed jointly by arGEN-X and a consortium of leading academic institutions in Belgium.

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

http://www.argen-x.com

About IWT

The agency for Innovation by Science and Technology (abbreviated as IWT) is the government agency founded in 1991 by the Flemish Government to support technological innovation projects in Flanders. Each year IWT distributes about EUR 300 million in subsidies for innovation projects to companies, organizations, research and educational institutions in Flanders. In addition to financial support, IWT also assists companies by, for instance helping them find the right information or the right partners at home or abroad, providing assistance with the preparation of projects for European programmes and with technology transfer throughout Europe. IWT
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
5. arGEN-X raises EUR 5 Million from PMV in Extension of EUR 32.5 Million Series B
6. Russian Government Starts Using Scopus for National Research Assessment
7. John Daly, Previous Merck Exec., Starts CTW Consulting Firm
8. FDA starts process to cut back antibiotic overuse in livestock
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 CVS Health Corporation (NYSE: CVS ... May 1, 2015, at 8:30 a.m. (EDT) with analysts ... An audio webcast of the conference call ... of the CVS Health website for all interested parties. ... webcast will be archived and available on the web ...
(Date:4/17/2015)... DIEGO , April 17, 2015  Trovagene, ... diagnostics, announced today that clinical data presented at ... that its urine-based Precision Cancer Monitoring ℠ ... and monitoring of EGFR T790M mutations ... Detection of EGFR T790M Mutation in Urinary ...
(Date:4/17/2015)... April 17, 2015  Over the next five years, the ... grow, with ArcView predicting that 14 more states will legalize ... The U.S. market for legal cannabis grew 74 percent in ... Analysts project the market could grow more than fourfold to ... soften their stance on marijuana. Cannabiz Mobile Inc. ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2
... BioVex Inc, a company developing next generation biologics ... announced today that the results from a Phase I/II combination ... will be presented at the 2009 American Society of Clinical ... 2009 - June 2, 2009 in Orlando, FL. The results ...
... on BIBW 2992, an Irreversible, Dual EGFR / HER2 ... NSCLC Patients with EGFR Activating Mutations - (1,2)-The First ... Conn., May 14 Boehringer Ingelheim will present new ... 2992 and BIBF 1120 at the 2009 Annual Meeting ...
Cached Medicine Technology:BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 2BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 3BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:4/18/2015)... (PRWEB) April 18, 2015 “ ArcAngel ” ... which takes a look at the latest and coolest ... Joe Troohey, the host of AppWatch and technology expert, conducted ... a personal safety app. , In a turbulent world, ... help. Calling 911 should always be their first move, but ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... system of this mosquito is of great importance as scientists ... of viruses that cause yellow and dengue fevers ... genes that make up the immune system of the Aedes ... been identified. ,This study is the first of ...
... the airplane, is about to be connected, allowing travellers to ... off cell phones and fasten seatbelts are a familiar ... European company has found a way to make dialling safe ... ,"Cabin connectivity is here and GSM phone use is both ...
... a healthy diet rich in fish and nuts could be ... to prostate cancer, new US research indicates . A study ... Investigation found that omega-3 fatty acids found in the foods ... to the condition. Working with mice genetically engineered to develop ...
... an ancient retrovirus that infected chimps and other primates millions ... species is susceptible to HIV, said a study released Thursday. ... against a four-million-year-old virus, called Pan troglodytes endogenous retrovirus, or ... most retroviruses, it inserts its DNA into the genome of ...
... urate in the blood is linked to a reduced risk ... at the Harvard School of Public Health (HSPH), was led ... ,Urate is a normal component of blood, and although ... beneficial effects because it is a potent antioxidant. ...
... Thursday said that all villages affected by chikungunya fever ... spread awareness among people even as 17,000 suspected ... this year. ,'We have asked the nine chikungunya-affected ... National Rural Health Mission, we will provide Rs.10,000 each ...
Cached Medicine News:Health News:Aedes Agypti Mosquitos Immune System Revealed 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 3Health News:Ancient Viral Defense may Explain Susceptibility to HIV: Study 2Health News:High Urate Levels in Blood Linked to Reduced Parkinson's Risk 2Health News:Chikungunya-hit Villages to Get Funds to Fight Mosquitoes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: